$CRMD
CorMedix Inc. Stock $crmd

$crmd Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024091961 Filed on October 30, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$11.46M	$0.00
YoY Change			-100.0%
Cost Of Revenue		$686.6K	$0.00
YoY Change			-100.0%
Gross Profit		$10.77M	$0.00
YoY Change			-100.0%
Gross Profit Margin		94.01%
Selling, General & Admin		$13.33M	$13.38M
YoY Change		70.82%	139.98%
% of Gross Profit		123.77%
Research & Development		$727.1K	$2.289M
YoY Change		-72.71%	-19.5%
% of Gross Profit		6.75%
Depreciation & Amortization		$77.41K	$18.67K
YoY Change		287.05%	-17.1%
% of Gross Profit		0.72%
Operating Expenses		$14.06M	$15.67M
YoY Change		34.29%	86.12%
Operating Profit		-$3.287M	-$15.67M
YoY Change		-68.59%	86.77%
Interest Expense		$510.5K	$914.7K
YoY Change		3793.24%	407.41%
% of Operating Profit
Other Income/Expense, Net		$510.5K
YoY Change		-29.38%
Pretax Income		-$2.777M	-$14.75M
YoY Change		-71.49%	79.73%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$2.777M	-$14.75M
YoY Change		-71.5%	79.73%
Net Earnings / Revenue		-24.24%
Basic Earnings Per Share		-$0.05
Diluted Earnings Per Share		-$0.05	-$0.26
COMMON SHARES
Basic Shares Outstanding	60.68M shares	55.86M shares	54.81M shares
Diluted Shares Outstanding		58.83M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.03M	$76.03M
YoY Change	-46.84%	29.32%
Cash & Equivalents	$35.29M	$43.64M
Short-Term Investments	$10.74M	$32.39M
Other Short-Term Assets	$3.088M	$1.313M
YoY Change	25.01%	73.07%
Inventory	$6.649M	$2.106M
Prepaid Expenses	$170.7K	$353.6K
Receivables	$17.39M
Other Receivables	$0.00
Total Short-Term Assets	$73.15M	$79.45M
YoY Change	-17.86%	33.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.900M	$1.866M
YoY Change	19.57%	15.94%
Goodwill
YoY Change
Intangibles	$1.896M	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$105.1K	$103.1K
YoY Change	5.08%	0.72%
Total Long-Term Assets	$4.432M	$2.610M
YoY Change	87.26%	4.92%
TOTAL ASSETS
Total Short-Term Assets	$73.15M	$79.45M
Total Long-Term Assets	$4.432M	$2.610M
Total Assets	$77.59M	$82.06M
YoY Change	-15.14%	32.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.344M	$4.280M
YoY Change	-43.68%	94.34%
Accrued Expenses	$16.97M	$6.970M
YoY Change	230.34%	75.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.48M	$11.40M
YoY Change	140.92%	80.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$393.0K	$517.0K
YoY Change	-29.83%	-22.56%
Total Long-Term Liabilities	$393.0K	$517.0K
YoY Change	-29.83%	-22.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.48M	$11.40M
Total Long-Term Liabilities	$393.0K	$517.0K
Total Liabilities	$18.87M	$11.92M
YoY Change	129.41%	70.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$353.1M	-$321.7M
YoY Change	15.03%	16.83%
Common Stock	$57.89K	$54.94K
YoY Change	5.61%	28.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$58.71M	$70.14M
YoY Change
Total Liabilities & Shareholders Equity	$77.59M	$82.06M
YoY Change	-15.14%	32.27%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$2.777M	-$14.75M
YoY Change	-71.5%	79.73%
Depreciation, Depletion And Amortization	$77.41K	$18.67K
YoY Change	287.05%	-17.1%
Cash From Operating Activities	-$13.65M	-$10.75M
YoY Change	57.08%	74.59%
INVESTING ACTIVITIES
Capital Expenditures	$9.760K	$295.9K
YoY Change	-2.4%	129.85%
Acquisitions
YoY Change
Other Investing Activities	$6.331M	$893.7K
YoY Change	-1191.58%	604.27%
Cash From Investing Activities	$6.321M	$597.8K
YoY Change	-1171.42%	-32239.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.07M	467.6K
YoY Change	-67.19%	-92.26%
NET CHANGE
Cash From Operating Activities	-13.65M	-10.75M
Cash From Investing Activities	6.321M	597.8K
Cash From Financing Activities	14.07M	467.6K
Net Change In Cash	6.746M	-9.680M
YoY Change	-79.94%	8611.53%
FREE CASH FLOW
Cash From Operating Activities	-$13.65M	-$10.75M
Capital Expenditures	$9.760K	$295.9K
Free Cash Flow	-$13.66M	-$11.04M
YoY Change	57.01%	75.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34673
	dei	Entity Registrant Name EntityRegistrantName	CORMEDIX INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5894890
	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Connell Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley Heights
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07922
	dei	City Area Code CityAreaCode	(908)
	dei	Local Phone Number LocalPhoneNumber	517-9500
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CRMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60677204	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35286138	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43642684	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	77453	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	10743562	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	32388130	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17387446	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	6649495	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106345	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	170739	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	353574	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2916889	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	882214	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31369	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21534874	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17659477	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13376081	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12515209	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	236615	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	198442	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	42878399	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1894285	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	253988	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15033751	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55449154	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-478	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8431970	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10126276	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35391222	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53501021	usd
	us-gaap	Interest Paid Net InterestPaidNet	26398	usd
	us-gaap	Interest Paid Net InterestPaidNet	27739	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2000000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3832	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	73154269	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	79450400	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1899875	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1866224	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1896104	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	105084	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	103055	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	530862	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640278	usd
CY2024Q3	us-gaap	Assets Assets	77586194	usd
CY2023Q4	us-gaap	Assets Assets	82059957	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1343833	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4279679	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16973677	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6970217	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	163449	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	150619	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18480959	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11400515	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	392967	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517013	usd
CY2024Q3	us-gaap	Liabilities Liabilities	18873926	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11917528	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57887149	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57887149	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54938258	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54938258	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	57886	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	54938	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	89120	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	94108	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	411659517	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	391693214	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-353094437	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321700013	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	58712268	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	70142429	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77586194	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82059957	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30222	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10007	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13113	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	26398	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	27740	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	510524	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	722929	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2503203	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1703846	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2776812	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9744354	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32789194	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31585198	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1394770	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2776812	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9744354	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31394424	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31585198	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-4571	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-3832	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1090	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1651	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1727	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3389	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6298	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4988	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2773423	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9750652	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31399412	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31583542	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58825221	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58825221	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56553174	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56553174	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57986190	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57986190	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48715585	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46183931	usd
CY2024Q3	us-gaap	Revenues Revenues	11456115	usd
	us-gaap	Revenues Revenues	12262234	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	686598	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2014975	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	10769517	usd
	us-gaap	Gross Profit GrossProfit	10247259	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	727119	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2663976	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2215551	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10866236	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6748900	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4058428	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20472961	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9955651	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6580834	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3744879	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22851144	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12467157	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	14056853	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	10467283	usd
	us-gaap	Operating Expenses OperatingExpenses	45539656	usd
	us-gaap	Operating Expenses OperatingExpenses	33289044	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3287336	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10467283	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35292397	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33289044	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	553856	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	765241	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2068407	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1761808	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-33325	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-29199	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-38806	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30222	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	500000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10007	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	13113	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	26398	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	27740	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	510524	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	722929	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2503203	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1703846	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2776812	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9744354	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32789194	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31585198	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1394770	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2776812	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9744354	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31394424	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31585198	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	5040	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-4571	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-3832	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	146324	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16973677	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6970217	usd
	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2000000	usd
	crmd	Additional Amount Of Achievement Of Milestones AdditionalAmountOfAchievementOfMilestones	500000	usd
CY2024Q3	crmd	License Agreement Payable Current LicenseAgreementPayableCurrent	2000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	150000000	usd
	crmd	Gross Proceeds Sale Of Common Stock Percentage GrossProceedsSaleOfCommonStockPercentage	0.03	pure
CY2024Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	100000000	usd
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2290024	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2521121	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	12367000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	13376000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	62241	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	103734	shares
CY2024Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	107000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	583000	usd
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	53000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	207000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1090	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1651	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1727	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1156	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	566	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3389	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6298	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4988	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1656	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2773423	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9750652	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31399412	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31583542	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58825221	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58825221	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56553174	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56553174	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57986190	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57986190	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48715585	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48715585	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46183931	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12366481	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1707803	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1227476	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3389	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2776812	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	58712268	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-236615	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4935500	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	58712268	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	42878399	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1002834	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6298	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9744354	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	83201822	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12515209	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	42878399	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	253988	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-198442	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4276474	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1656	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31585198	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	83201822	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31394424	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31585198	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12366481	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1707803	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1227476	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3389	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2776812	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	58712268	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	70142429	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13376081	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1894285	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-236615	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4935500	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4988	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31394424	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	58712268	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	49051109	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	42878399	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20132	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1002834	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6298	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9744354	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	83201822	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12515209	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	42878399	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	253988	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-198442	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4276474	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	83201822	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31394424	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31585198	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4935500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4276474	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	109416	usd
	us-gaap	Depreciation Depreciation	72210	usd
	us-gaap	Depreciation Depreciation	52085	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103896	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17387446	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4543150	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1851748	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1756105	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2935851	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	183903	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8002696	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1164571	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-111216	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-99486	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45000117	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27663786	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21475457	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60978108	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	43116192	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	43350000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105861	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31369	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21534874	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4935500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4276474	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	109416	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	99970	usd
	us-gaap	Depreciation Depreciation	72210	usd
	us-gaap	Depreciation Depreciation	52085	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103896	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17387446	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4543150	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1851748	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1756105	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2935851	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	183903	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8002696	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1164571	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-111216	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-99486	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45000117	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27663786	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	21475457	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60978108	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	43116192	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	43350000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105861	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13376081	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12515209	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	236615	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	198442	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	42878399	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1894285	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	253988	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15033751	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55449154	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-478	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10126276	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43823192	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53501021	usd
	us-gaap	Interest Paid Net InterestPaidNet	26398	usd
	us-gaap	Interest Paid Net InterestPaidNet	27739	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2000000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3832	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1090	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	236615	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1894285	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15033751	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8431970	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10126276	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43823192	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35391222	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3832	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Company’s consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain reclassifications were made to the prior year’s amounts to conform to the 2024 presentation.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of $11,456,000 and $12,262,000, respectively. This customer also accounts for 100% of the Company’s accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, taurolidine and heparin sodium.</p>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35286138	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53313811	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	105084	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	187210	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35391222	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53501021	usd
CY2024Q3	crmd	Common Stock Remaining Share Value Available For Sale CommonStockRemainingShareValueAvailableForSale	36012000	usd
	crmd	Common Stock Remaining Capacity CommonStockRemainingCapacity	100000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Company’s consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain reclassifications were made to the prior year’s amounts to conform to the 2024 presentation.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of $11,456,000 and $12,262,000, respectively. This customer also accounts for 100% of the Company’s accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, taurolidine and heparin sodium.</p>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35286138	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53313811	usd
CY2024Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	105084	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35391222	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53501021	usd
CY2024Q3	crmd	Common Stock Remaining Share Value Available For Sale CommonStockRemainingShareValueAvailableForSale	36012000	usd
	crmd	Common Stock Remaining Capacity CommonStockRemainingCapacity	100000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Company’s consolidated balance sheets and the reported amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates.</p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain reclassifications were made to the prior year’s amounts to conform to the 2024 presentation.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three and nine months ended September 30, 2024, the Company had sales to one customer that accounted for 98% and 92% of its total revenue of $11,456,000 and $12,262,000, respectively. This customer also accounts for 100% of the Company’s accounts receivable as of September 30, 2024. The Company currently has one FDA approved source for each of its two key active pharmaceutical ingredients for DefenCath, taurolidine and heparin sodium.</p>
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35286138	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53313811	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35391222	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53501021	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	33760120	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	254	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5503	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	33765369	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64920279	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1425	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10506	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1525420	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	961367	usd
CY2024Q3	crmd	Provisions For The Revenue Reserves ProvisionsForTheRevenueReserves	6598000	usd
	crmd	Provisions For The Revenue Reserves ProvisionsForTheRevenueReserves	6792000	usd
	crmd	Revenue Variable Consideration RevenueVariableConsideration	6753000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	33760120	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	254	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5503	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	33765369	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64920279	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64929360	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	603545	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1525420	usd
CY2024Q3	crmd	Provisions For The Revenue Reserves ProvisionsForTheRevenueReserves	6598000	usd
	crmd	Revenue Variable Consideration RevenueVariableConsideration	6753000	usd
CY2024Q3	us-gaap	Derivative Underlying Investment Shares DerivativeUnderlyingInvestmentShares	2500625	shares
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	33760120	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	254	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5503	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	33765369	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64920279	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1425	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10506	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	64929360	usd
	crmd	Inventories Expensed As Research And Development InventoriesExpensedAsResearchAndDevelopment	6177000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	603545	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1525420	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	5084583	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	580925	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	961367	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	6649495	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106345	usd
	crmd	Revenue Variable Consideration RevenueVariableConsideration	6753000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11428673	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13428202	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11428673	shares
CY2024Q3	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	1066987	usd
CY2024Q3	crmd	Food And Drug Administration Filling Fee FoodAndDrugAdministrationFillingFee	599411	usd
CY2024Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	505627	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2916889	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	882214	usd
CY2024Q3	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	1066987	usd
CY2024Q3	crmd	Food And Drug Administration Filling Fee FoodAndDrugAdministrationFillingFee	599411	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	118091	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2916889	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	882214	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4788529	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2718770	usd
CY2024Q3	crmd	Manufacturing Development Current ManufacturingDevelopmentCurrent	3037736	usd
CY2023Q4	crmd	Manufacturing Development Current ManufacturingDevelopmentCurrent	1835101	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	584374	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2270022	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191995	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	146324	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16973677	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6970217	usd
	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2000000	usd
	crmd	Additional Amount Of Achievement Of Milestones AdditionalAmountOfAchievementOfMilestones	500000	usd
CY2024Q3	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	1066987	usd
CY2024Q3	crmd	Food And Drug Administration Filling Fee FoodAndDrugAdministrationFillingFee	599411	usd
CY2024Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	505627	usd
CY2023Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	171393	usd
CY2024Q3	crmd	Prepaid Subscriptions Current PrepaidSubscriptionsCurrent	301291	usd
CY2023Q4	crmd	Prepaid Subscriptions Current PrepaidSubscriptionsCurrent	466114	usd
CY2024Q3	crmd	Prepaid Medical Affairs Current PrepaidMedicalAffairsCurrent	198048	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	94246	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	126616	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	151279	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	118091	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2916889	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	882214	usd
CY2024Q3	crmd	Accrued Grosstonet Deduction AccruedGrosstonetDeduction	-6371043	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4788529	usd
CY2024Q3	crmd	Manufacturing Development Current ManufacturingDevelopmentCurrent	3037736	usd
CY2024Q3	crmd	License Agreement Payable Current LicenseAgreementPayableCurrent	2000000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	584374	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2270022	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	146324	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16973677	usd
	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2000000	usd
	crmd	Additional Amount Of Achievement Of Milestones AdditionalAmountOfAchievementOfMilestones	500000	usd
CY2024Q3	crmd	License Agreement Payable Current LicenseAgreementPayableCurrent	2000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	150000000	usd
	crmd	Gross Proceeds Sale Of Common Stock Percentage GrossProceedsSaleOfCommonStockPercentage	0.03	pure
CY2024Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	100000000	usd
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2290024	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	12367000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2718770	usd
CY2024Q3	crmd	Manufacturing Development Current ManufacturingDevelopmentCurrent	3037736	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2270022	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191995	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	146324	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16973677	usd
	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2000000	usd
	crmd	Additional Amount Of Achievement Of Milestones AdditionalAmountOfAchievementOfMilestones	500000	usd
CY2024Q3	crmd	License Agreement Payable Current LicenseAgreementPayableCurrent	2000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	150000000	usd
	crmd	Gross Proceeds Sale Of Common Stock Percentage GrossProceedsSaleOfCommonStockPercentage	0.03	pure
CY2024Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	100000000	usd
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2290024	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	62241	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	103734	shares
CY2024Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	107000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	583000	usd
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	53000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	207000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2024Q3	crmd	License Agreement Payable Current LicenseAgreementPayableCurrent	2000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	150000000	usd
	crmd	Gross Proceeds Sale Of Common Stock Percentage GrossProceedsSaleOfCommonStockPercentage	0.03	pure
CY2024Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	100000000	usd
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2290024	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2521121	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	12367000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	62241	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	103734	shares
CY2024Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	107000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	583000	usd
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	53000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2024Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9885	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0415	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	62241	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	103734	shares
CY2024Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	107000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	583000	usd
CY2023Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense	53000	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	207000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9885	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0415	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2024Q3	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	51000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	153000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9885	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0415	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2024Q3	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	51000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	153000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	155000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	531000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640000	usd
CY2024Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	51000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M26D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9885	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0415	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2024Q3	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	51000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	153000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	155000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	163000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	393000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	531000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	153000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	50000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	208000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	639000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2024Q3	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	51000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	153000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	52000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	155000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	531000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	153000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	50000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	150000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	51000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	208000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	211000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	639000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
	us-gaap	Revenues Revenues		usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	155000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	163000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	393000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	668000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	517000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	531000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	640000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	150000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	51000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	208000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	211000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	639000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
CY2023Q4	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther		usd
CY2023Q4	crmd	Food And Drug Administration Filling Fee FoodAndDrugAdministrationFillingFee		usd
CY2023Q4	crmd	Prepaid Medical Affairs Current PrepaidMedicalAffairsCurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Operating Lease Payments OperatingLeasePayments	153000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	50000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	150000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	51000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	208000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	211000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	639000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2023Q4	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther		usd
CY2023Q4	crmd	Prepaid Medical Affairs Current PrepaidMedicalAffairsCurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001410098
	us-gaap	Revenues Revenues		usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q3	us-gaap	Gross Profit GrossProfit		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
CY2023Q4	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther		usd
CY2023Q4	crmd	Food And Drug Administration Filling Fee FoodAndDrugAdministrationFillingFee		usd
CY2023Q4	crmd	Prepaid Medical Affairs Current PrepaidMedicalAffairsCurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
CY2023Q4	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther		usd
CY2023Q4	crmd	Food And Drug Administration Filling Fee FoodAndDrugAdministrationFillingFee		usd
CY2023Q4	crmd	Prepaid Medical Affairs Current PrepaidMedicalAffairsCurrent		usd
CY2023Q4	crmd	Accrued Grosstonet Deduction AccruedGrosstonetDeduction		usd
CY2023Q4	crmd	License Agreement Payable Current LicenseAgreementPayableCurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3

Files In Submission

Name	View Source	Status
0001213900-24-091961-index-headers.html	Edgar Link	pending
0001213900-24-091961-index.html	Edgar Link	pending
0001213900-24-091961.txt	Edgar Link	pending
0001213900-24-091961-xbrl.zip	Edgar Link	pending
crmd-20240930.xsd	Edgar Link	pending
ea0218371-10q_cormedix.htm	Edgar Link	pending
ea021837101ex31-1_cormedix.htm	Edgar Link	pending
ea021837101ex31-2_cormedix.htm	Edgar Link	pending
ea021837101ex32-1_cormedix.htm	Edgar Link	pending
ea021837101ex32-2_cormedix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
crmd-20240930_cal.xml	Edgar Link	unprocessable
crmd-20240930_pre.xml	Edgar Link	unprocessable
crmd-20240930_def.xml	Edgar Link	unprocessable
crmd-20240930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0218371-10q_cormedix_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
0001213900-24-091961-index-headers.html	Edgar Link	pending
0001213900-24-091961-index.html	Edgar Link	pending
0001213900-24-091961.txt	Edgar Link	pending
0001213900-24-091961-xbrl.zip	Edgar Link	pending
crmd-20240930.xsd	Edgar Link	pending
ea0218371-10q_cormedix.htm	Edgar Link	pending
ea021837101ex31-1_cormedix.htm	Edgar Link	pending
ea021837101ex31-2_cormedix.htm	Edgar Link	pending
crmd-20240930_cal.xml	Edgar Link	unprocessable
crmd-20240930_def.xml	Edgar Link	unprocessable
crmd-20240930_pre.xml	Edgar Link	unprocessable
crmd-20240930_lab.xml	Edgar Link	unprocessable
ea0218371-10q_cormedix_htm.xml	Edgar Link	completed
ea021837101ex32-1_cormedix.htm	Edgar Link	pending
ea021837101ex32-2_cormedix.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRMD
CorMedix Inc. Stock $crmd

2024 Q4 Form 10-Q Financial Statement

#000121390024091961 Filed on October 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD CorMedix Inc. Stock $crmd

2024 Q4 Form 10-Q Financial Statement

#000121390024091961 Filed on October 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD
CorMedix Inc. Stock $crmd